Description:
- Targeted and timed release of therapeutics via bone anchoring
Abstract
USC researchers have developed a targeted and timed release of therapeutics via bone anchoring to treat sensorineural hearing loss (SNHL). This approach expands on bisphosphonates’ ability to target and remain at bone sites by implementing a specifically designed cleavable linker that allows for controlled release of the drug from the bone-anchored conjugate at physiological pH, enabling sustained therapeutic concentrations. The linker's structure can be synthetically modified to adjust the drug release rate, providing a tailored delivery profile. This "target and timed release" (TATR) technology ensures prolonged drug presence within the inner ear, potentially improving treatment efficacy for SNHL.
Benefit
- Sustained Drug Release: Tenfold improvement within the inner ear, ensuring prolonged therapeutic concentrations for SNHL.
- Targeted Delivery: Strong affinity to bone enables targeted delivery of the drug to the inner ear.
- Controlled Release Profile: Cleavable linker allows for controlled release of the drug at physiological pH, with the release rate adjustable by modifying the linker structure.
Market Application
Hearing loss, sensorineural hearing loss
Publications
10.1021/acs.bioconjchem.8b00022